Multiple enzymes

Multiple enzymes is a non-specific, aggregate term rather than a single molecular target. In the context of pharmacology and drug discovery, this designation typically describes a therapeutic strategy involving multi-target directed ligands (MTDLs) or polypharmacology, where a single drug is designed to interact with several different enzymes to achieve a synergistic effect or overcome resistance (ResearchGate, 2020; MDPI, 2021). This approach is common in treating complex, multifactorial diseases such as cancer, where a drug might inhibit several kinases, or in inflammatory conditions where multiple pathways in the arachidonic acid cascade are targeted (bioRxiv, 2024; NIH, 2020). Because it does not identify a specific molecular entity—such as a particular protein or gene product—Multiple enzymes is considered an aggregate category rather than a valid canonical target for precise drug annotation. Instead, it serves as a conceptual grouping for drugs that exhibit broad-spectrum activity across various enzymatic pathways to enhance therapeutic efficacy and reduce the likelihood of escape mutations in pathogens or tumors (BOC Sciences, 2024).

Other names

Multi-targetPolypharmacology targetsEnzyme groupMulti-enzyme complex

Simultaneous modulation of multiple enzymatic proteins to disrupt complex disease networks or overcome compensatory pathways.